Rabeprazole: all 123 studies that test it

Page 1 of 2. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21)Not yet recruitingNCT07888569Phase 1
• Efficacy And Safety of Bismuth-Tetracycline-Rabeprazole Triple For First-Line Eradication of Helicobacter Pylori InfectionNot yet recruitingNCT07788053Not applicable
• Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRventionRecruitingNCT07471867Phase 4
• A Study of Maribavir Pediatric Formulation in Healthy Adult ParticipantsCompletedNCT05918822Phase 1Results posted
• Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of CamlipixantCompletedNCT05899829Phase 1Results posted
• A Relative Bioavailability Study Evaluating Two New Encorafenib FormulationsCompletedNCT05446142Phase 1Results posted
• A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the BloodCompletedNCT05380947Phase 1Results posted
• Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy VolunteersCompletedNCT03530995Phase 1Results posted
• Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed ConditionsCompletedNCT02605395Phase 4Results posted
• A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After a Single Oral Dose Administration Under Fasting Conditions in Healthy AdultsCompletedNCT02446483Phase 4Results posted
• A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease PatientsCompletedNCT02135107Phase 3Results posted
• Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)CompletedNCT02037477Phase 3Results posted
• Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)CompletedNCT01398410Phase 2/3Results posted
• Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)CompletedNCT01397448Phase 2/3Results posted
• A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy ParticipantsCompletedNCT01277718Phase 1Results posted
• A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)CompletedNCT01202071Phase 2Results posted
• A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)CompletedNCT01089543Phase 2Results posted
• An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux EsophagitisCompletedNCT01008696Phase 4Results posted
• Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)CompletedNCT00992589Phase 3Results posted
• Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)CompletedNCT00911534Phase 3Results posted
• Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)CompletedNCT00839306Phase 3Results posted
• Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic UlcersTerminatedNCT00838682Phase 4Results posted
• Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)CompletedNCT00838526Phase 3Results posted
• A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric PatientsCompletedNCT00787891Phase 3Results posted
• Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux EsophagitisCompletedNCT00770913Phase 2/3Results posted
• Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)CompletedNCT00658775Phase 3Results posted
• Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)CompletedNCT00658632Phase 3Results posted
• Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)CompletedNCT00658528Phase 3Results posted
• A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mgCompletedNCT00464308Phase 4Results posted
• E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent SufferersCompletedNCT00236197Phase 3Results posted
• E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent SufferersCompletedNCT00236184Phase 3Results posted
• Maintenance Intermittent Therapy for Symptomatic GERD PatientsCompletedNCT00165841Phase 2Results posted
• A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux DiseaseCompletedNCT00165672Phase 3Results posted
• A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux DiseaseCompletedNCT00165646Phase 3Results posted
• Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With RabeprazoleCompletedNCT00132496Phase 2Results posted
• A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 CapsulesCompletedNCT07643272Phase 1
• Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 TabletsActive, not recruitingNCT07608666Phase 1
• A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy AdultsCompletedNCT07597928Phase 1
• A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.CompletedNCT07284173Phase 1
• Helicobacter Pylori Infection and Gastric Disease in Bhutan: First Community-Wide, Population-Based StudyCompletedNCT07211880Not applicable
• Evaluate the Effects of Famotidine or Rabeprazole on the PK of NirogacestatCompletedNCT07171619Phase 1
• Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy VolunteersCompletedNCT06787131Phase 1
• Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy VolunteersCompletedNCT06399315Phase 1
• HMPL-453 Food Effect and PPI Study in Healthy Volunteer StudyCompletedNCT05930119Phase 1
• HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPICompletedNCT05602597Phase 1
• HMPL-523 Food Effect and Proton Pump Inhibitor StudyCompletedNCT05571787Phase 1
• 14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid TherapyStatus unknownNCT05191888Phase 4
• A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult SubjectsCompletedNCT04703868Phase 1
• A Study to Compare PK, PD and Safety of the AD-214-02 and RabeprazoleCompletedNCT04622358Phase 1
• A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy ParticipantsCompletedNCT04565574Phase 1
• A Study to Compare PK, PD and Safety of the AD-214 10/600mg and RabeprazoleCompletedNCT04494243Phase 1
• A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy ParticipantsCompletedNCT04489797Phase 1
• The Epidemiology and Optimal Treatment of Helicobacter Pylori in MyanmarCompletedNCT04132479Phase 4
• Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.CompletedNCT04001400Phase 3
• A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy ParticipantsCompletedNCT03979248Phase 1
• Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori EradicationStatus unknownNCT03802318Not applicable
• Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of VadadustatCompletedNCT03789032Phase 1
• Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori InfectionCompletedNCT03521726Phase 4
• Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer DiseasesCompletedNCT03320538Not applicable
• A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy ParticipantsCompletedNCT03290703Phase 1
• Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of PalbociclibCompletedNCT03220191Phase 1
• 10 vs 14 Days Triple Therapy : H.Pylori Infection EradicationStatus unknownNCT03134378Phase 4
• Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter PyloriCompletedNCT03108287Phase 4
• Effect of Proton Pump Inhibitors on PalpitationsCompletedNCT02826408Not applicable
• The Effect of Dexrabeprazole on Intragastric and Intraesophageal AcidityCompletedNCT02689999Phase 4
• A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral SclerosisCompletedNCT02655614Phase 1
• PPI And Food Effect Study For PF-06463922 In Healthy VolunteersCompletedNCT02569554Phase 1
• Personalized Treatment for Refractory H Pylori InfectionCompletedNCT02547025Not applicable
• To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male SubjectsCompletedNCT02509923Phase 1
• A Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT)CompletedNCT02477306Phase 1
• A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy ParticipantsCompletedNCT02475161Phase 1
• A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of PalbociclibCompletedNCT02311946Phase 1
• Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And FoodCompletedNCT02097329Phase 1
• Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fed ConditionsCompletedNCT01990586Phase 1
• Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fasted ConditionsCompletedNCT01990378Phase 1
• A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive TumorsCompletedNCT01954043Phase 1
• Concomitant Therapy of H. PyloriStatus unknownNCT01922765Phase 4
• Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)CompletedNCT01918176Phase 1
• The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERDCompletedNCT01860482Phase 4
• A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of VismodegibCompletedNCT01772290Phase 1
• Effects of YF476 and Rabeprazole on Gastric FunctionCompletedNCT01699113Phase 1
• Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple TherapyStatus unknownNCT01572597Phase 4
• New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection：a Pilot StudyCompletedNCT01513785Phase 2
• ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASACompletedNCT01408186Phase 3
• Effects of Gastric pH on the Pharmacokinetics of DasatinibCompletedNCT01398046Phase 1
• Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERDWithdrawnNCT01391715Phase 3
• A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the TabletCompletedNCT01287091Phase 1
• A Bioequivalence Study of 2 Formulations of Rabeprazole Sodium and Evaluation of the Effect of Food on Rabeprazole Sodium in Healthy Adult VolunteersCompletedNCT01241409Phase 1
• A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori InfectionCompletedNCT01219764Phase 4
• A Relative Bioavailability Study of Rabeprazole Sodium Administered With Different Dosing Vehicles in Healthy Adult VolunteersCompletedNCT01186497Phase 1
• A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg TabletsCompletedNCT01153659Phase 1
• A Study of Rabeprazole for Prevention of Non Steroidal Anti-inflammatory Drug -Associated Gastroduodenal InjuryCompletedNCT01140828Phase 3
• Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese SubjectsCompletedNCT01136317Phase 2
• A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult VolunteersCompletedNCT01101646Phase 1
• A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition)CompletedNCT01085708Phase 1
• Study of E3810 for Healthy Japanese Male (Under Fasting Condition)CompletedNCT01085695Phase 1
• Cardio-cerebrovascular Disease and Aspirin Ulcer Relapse EvaluationCompletedNCT01051388Phase 3
• Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal BleedingStatus unknownNCT00861640Phase 4
• A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)CompletedNCT00855361Phase 1
• Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal ResectionCompletedNCT00844675Phase 4

← Rabeprazole overview